People with ulcerative colitis undergo surveillance for dysplasia because of an increased risk of colorectal cancer. This case highlights a pathology pattern (pseudocarcinomatous invasion) that can mimic invasive...

A more detailed, reproducible measure of endoscopic inflammation could better reflect total disease burden and reduce variability from human readers. That may matter for monitoring disease activity, judging treatment...

The article helps patients and caregivers recognize common symptoms and complications, understand causes and risk factors, and see why ongoing specialist care and lifestyle measures matter for long-term management.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...

This trial tests an investigational oral therapy (D-2570) specifically in moderate–severe ulcerative colitis with a standard clinical remission endpoint at 12 weeks. Results could inform new treatment options if later...

This trial tests whether adding an investigational oral agent (LY4268989) to mirikizumab improves remission rates in people with moderately to severely active ulcerative colitis. If successful, it could expand treatment...

Patients and clinicians care about objective, reliable ways to tell if intestinal inflammation is truly healed because histologic healing predicts outcomes.

Changes in gut permeability are thought to relate to intestinal barrier function and symptoms in UC and IBS-D. If Aquamin alters permeability, it could suggest a mechanism for symptom or disease-modifying effects and...

This trial tests mirikizumab (an anti–IL-23p19 biologic) alone and with an oral agent in adults with moderate–severe UC or CD, which could expand treatment options if later-phase trials are successful.

This trial tests whether adding an FXR agonist (LY4395089) to mirikizumab improves endoscopic response in people with moderate–severe Crohn's disease. Results could influence future combination treatment strategies and...

This trial tests a new oral drug for moderate-to-severe ulcerative colitis and could expand treatment options if later shown to be safe and effective. It also targets patients who have had inadequate response or...

This trial tests a common real-world question: switching from IV induction to subcutaneous vedolizumab maintenance in adults with moderate-to-severe UC or CD and measures short-term remission and longer-term treatment...

Surgery is common in Crohn’s disease and different types of resections carry different short-term risks.

Noninvasive monitoring matters for children with UC because endoscopy is burdensome. If ultrasound (and simple measures like bowel wall thickness) can reliably detect moderate-to-severe disease, families may avoid some...

The study suggests a plant-derived AHR-activating mechanism that reduced inflammation and repaired the intestinal barrier in preclinical ulcerative colitis models, a pathway that could be relevant to future therapies or...

If you have newly diagnosed Crohn’s disease, this study suggests sacroiliac joint inflammation or structural SIJ changes can already be present and may relate to microscopic (histologic) intestinal activity.

Intravenous iron is frequently used in people with IBD who have iron deficiency anaemia. A change in which iron formulation hospitals use could affect healthcare spending and potentially access to treatment.

The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...

Zinc deficiency is common in UC, and this study suggests that changes in zinc‑dependent enzyme activity in the gut lining are linked with local inflammation. If confirmed, mucosal enzyme activity might help explain...

Based on the title and source metadata, this appears to be a case report related to Inflammatory bowel disease and Complications. The original article is from Immunopharmacology and Immunotoxicology.

This is relevant because military aviators with Crohn’s disease have historically been excluded from waivers; policy changes could allow some stable patients to continue flying if objective evidence supports low...

Reliable laboratory methods help ensure upadacitinib tablets contain the correct amount of drug and support quality control of medicines people take for conditions including Crohn’s disease and ulcerative colitis.

Cure8 indexed source-provided abstract text from OpenAlex, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Colorectal cancer, Inflammatory bowel disease, and Complications.

Non-invasive urine biomarkers could make diagnosis and disease-activity monitoring easier and less invasive for people with IBD. Identifying metabolites linked to UC activity may help tailor monitoring without frequent...

Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...

This study identifies factors linked to permanent ileal pouch failure after surgery for ulcerative colitis and provides a nomogram to estimate individual risk — information that can affect surgical counseling and...

Dietary strategies that reduce inflammation and oxidative stress could complement medical care for people with IBD by potentially lowering biomarkers linked to disease activity.

The study links depleted fatty acid oxidation metabolites—especially butyrate—to impaired regulatory T cell development in IBD, suggesting a metabolic pathway that may influence immune tolerance and disease activity.

A traditional medicine formulation (Hudi capsules) relieved colitis signs in mice and appears to stimulate Wnt/β-catenin–dependent epithelial regeneration, which could point to new therapeutic directions for mucosal...

A new biologic (duvakitug) targeting TL1A showed higher clinical remission at 14 weeks than placebo in a phase 2b trial of adults with moderately to severely active ulcerative colitis, which could expand future treatment...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Tests and monitoring. The original article is from Journal of Gastroenterology...

The review suggests MSCs and their exosomes can change the gut microbiome, a factor implicated in IBD and liver disease, pointing to a potential new therapeutic approach. Patients and clinicians interested in future IBD...

If therapies that restore intestinal barrier function can be reliably tested and measured, future treatments might be developed that specifically target barrier healing — a mechanism linked to symptom relief and possibly...

The study shows that more children worldwide are living with early-onset IBD even as mortality has fallen, and it highlights persistent socioeconomic disparities—important for families and clinicians tracking pediatric...

Markers of systemic inflammation (CRP and ESR) were consistently higher in people with obesity across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis, suggesting body weight may influence...

Patients and clinicians choosing first‑line biologic therapy for ulcerative colitis may find evidence here that vedolizumab can provide sustained clinical benefit and a favorable safety profile in a biologic‑naïve...

Subcutaneous infliximab may let children on infliximab avoid regular IV infusions while keeping drug levels high and maintaining remission. Results are relevant to families and clinicians considering switching pediatric...

Cure8 found this source from BMC Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, AI and data science, and Colonoscopy. Open the original article for the full...

Some people with ulcerative colitis seek complementary or herbal treatments. This review reports research on a modified Gegen Qinlian Decoction that the authors say may strengthen the gut barrier and reduce inflammation,...

This large, population-based study tests whether exposure to outdoor artificial light at night is linked to getting IBD or to later health-care use. Understanding environmental factors that might influence IBD risk or...

Cure8 found this source from crohnscolitisfoundation.org, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and awareness. Open the original article...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...

The study uses single-cell RNA sequencing to pinpoint genes and regulatory networks that might help explain IBD biology and suggest new biomarkers or repurposed drugs. That information could guide future research toward...

Cure8 found this source from BMC Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Tests and monitoring. Open the original article for the full details.

Researchers tested manumycin A in a standard mouse colitis model and observed reduced inflammation and tissue injury, suggesting the compound might be a candidate for further IBD drug development.

New PET tracers like FAPI could better detect fibrosis and stromal activity than standard FDG-PET, which may improve imaging of fibrostenotic Crohn's disease. For people with IBD, improved imaging might eventually help...

Point-of-care intestinal ultrasound (IUS) showed strong agreement with follow-up tests and often changed management the same day in a New Zealand IBD cohort. Patients and clinicians may be able to use IUS to monitor...